Butyrylcholinesterase- Qrono

Drug Profile

Butyrylcholinesterase- Qrono

Alternative Names: Butyrylcholinesterase Qx; QR 205

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Qrono
  • Class Antidotes; Cholinesterases
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Unspecified

Highest Development Phases

  • Clinical Phase Unknown Unspecified

Most Recent Events

  • 04 Aug 2017 Butyrylcholinesterase- Qrono is available for licensing as of 04 Aug 2017. http://qrono.com/pipeline/ (Qrono pipeline, August 2017)
  • 04 Aug 2017 Clinical trials in Undefined indication in USA (Parenteral) (Qrono pipeline, August 2017)
  • 04 Aug 2017 Early research in Undefined indication in USA (Parenteral) before August 2017 (Qrono pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top